How a big biotech’s start-up gamble went wrong
Behind the Money
The Importance of FDA Approval for Grail Tests
Illumina's 80% market share meant that the company had been able to make their investors a lot of consistent money for many years. While grail was working on getting that full FDA approval, the startup actually began selling its test in 2021 - making it available to people in the US with a doctor's prescription. Jamie says not everyone feels like Valerie. We've got a lot of critics out there who say they're trying to sell these things to the public before they're fully proven that they actually work. They haven't done enough testing and they haven't done the right trials yet to really prove that these products should be out in the market.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
